Abstract
BackgroundNatural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have